Introduction
The incidence of infectious complications following Caesarean section has been reported to be as high as 48 to 85 per cent (Gibbs et al., 1978; de Palma et al., 1980) . It is significantly higher in emergency cases as compared with patients undergoing elective surgery (Hagglund et al., 1983) . The importance of prophylactic administration of antibiotics to these patients at risk has been unequivocally demonstrated (Polk, 1981) .
Since anaerobic bacteria are often involved in these and other gynaecological diseases (Gilstrap & Cunningham, 1979; Middleton et al., 1980; Dizerega et al., 1980) nitroimidazoles have been suggested to be the drugs of choice in cases of emergency Caesarean section (Vaughan, 1979; Gerstner et al., 1980) . The efficacy of nitroimidazoles used prophylactically in these patients has been well documented (Vaughan, 1979; Gerstner et al., 1980) as has the low frequency of side effects (Andersson, 1981) . So far no adverse effects of nitroimidazoles have been demonstrated in neonates (Amon et al., 1972) . Nevertheless, the use of these drugs at Caesarean section necessitates studies of their pharmacokinetics in the mother as well as of the breast milk excretion. Whilst metronidazole pharmacokinetics and breast milk excretion have been studied (Erickson et al., 1981; Heisterberg & Branebjerg, 1983) 
Results
The start of the milk production, the daily volumes produced during the first 96 h after surgery, as well as the total amounts of tinidazole excreted in the breast milk are displayed in Table 2 . During the first 24 h after the infusion no or very little milk was produced. Nevertheless, in patients 2 and 3 significant amounts of tinidazole were excreted during the first day. There was a large interindividual variation in milk volumes and excreted drug. Thus, patient 1 was found to Prolonged labour + 'macrosomia' excrete several fold larger amounts than all other women. The excretion of tinidazole in breast milk was highly related to the serum concentration in each individual patient (Figure 1) (Mattila et al., 1983) and men (Charuel et al., 1981 (Rane, 1980) . A The observation in patient no 4 marked (0) has been excluded from the calculation of the regression line. different approach may be taken if one considers how large a fraction of the maternal body content of drug that will be transferred daily to the infant at a given milk secretion rate. If one assumes a Vd of 1 1/kg and a daily milk volume of 0.5 1 only 0.7 % of the maternal body content will be transferred to the baby (assuming a milk/ serum concentration ratio of 1.0).
It is our opinion that breast feeding may start 3 days after prophylactic treatment with 1600 mg tinidazole i.v., the estimated exposure to tinidazole being considered minimal and probably neglectable.
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